PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel chec… Read more
Market Cap & Net Worth: PharmaEssentia (6446)
PharmaEssentia (TW:6446) has a market capitalization of $6.64 Billion (NT$219.56 Billion) as of March 18, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #2484 globally and #45 in its home market, demonstrating a -4.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaEssentia's stock price NT$657.00 by its total outstanding shares 334187000 (334.19 Million).
PharmaEssentia Market Cap History: 2015 to 2026
PharmaEssentia's market capitalization history from 2015 to 2026. Data shows growth from $1.90 Billion to $6.64 Billion (20.66% CAGR).
PharmaEssentia Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaEssentia's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.64x
PharmaEssentia's market cap is 0.64 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.09x
PharmaEssentia's market cap is 2.09 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.90 Billion | $11.59 Million | -$853.20 Million | 164.22x | N/A |
| 2016 | $1.63 Billion | $5.47 Million | -$844.92 Million | 298.05x | N/A |
| 2017 | $1.44 Billion | $4.04 Million | -$872.31 Million | 357.96x | N/A |
| 2018 | $1.76 Billion | $26.24 Million | -$1.04 Billion | 67.18x | N/A |
| 2019 | $1.11 Billion | $305.69 Million | -$842.99 Million | 3.63x | N/A |
| 2020 | $947.43 Million | $557.26 Million | -$1.95 Billion | 1.70x | N/A |
| 2021 | $2.96 Billion | $656.51 Million | -$2.81 Billion | 4.51x | N/A |
| 2022 | $4.82 Billion | $2.88 Billion | -$1.37 Billion | 1.67x | N/A |
| 2023 | $3.49 Billion | $5.11 Billion | -$623.84 Million | 0.68x | N/A |
| 2024 | $6.21 Billion | $9.73 Billion | $2.97 Billion | 0.64x | 2.09x |
Competitor Companies of 6446 by Market Capitalization
Companies near PharmaEssentia in the global market cap rankings as of March 18, 2026.
Key companies related to PharmaEssentia by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
PharmaEssentia Historical Marketcap From 2015 to 2026
Between 2015 and today, PharmaEssentia's market cap moved from $1.90 Billion to $ 6.64 Billion, with a yearly change of 20.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$6.64 Billion | +39.79% |
| 2025 | NT$4.75 Billion | -23.58% |
| 2024 | NT$6.21 Billion | +77.75% |
| 2023 | NT$3.49 Billion | -27.46% |
| 2022 | NT$4.82 Billion | +62.80% |
| 2021 | NT$2.96 Billion | +212.37% |
| 2020 | NT$947.43 Million | -14.73% |
| 2019 | NT$1.11 Billion | -36.96% |
| 2018 | NT$1.76 Billion | +22.03% |
| 2017 | NT$1.44 Billion | -11.46% |
| 2016 | NT$1.63 Billion | -14.29% |
| 2015 | NT$1.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of PharmaEssentia was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.64 Billion USD |
| MoneyControl | $6.64 Billion USD |
| MarketWatch | $6.64 Billion USD |
| marketcap.company | $6.64 Billion USD |
| Reuters | $6.64 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.